H.C. Wainwright Sticks to Their Buy Rating for Alimera (ALIM)


In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Alimera (ALIM), with a price target of $2.75. The company’s shares closed yesterday at $1.09.

According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -5.6% and a 29.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

Currently, the analyst consensus on Alimera is a Moderate Buy with an average price target of $2.90, representing a 166.1% upside. In a report released yesterday, B.Riley FBR also maintained a Buy rating on the stock with a $3.05 price target.

See today’s analyst top recommended stocks >>

Based on Alimera’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $1.25 million. In comparison, last year the company had a GAAP net loss of $7.22 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts